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SUMMARY 
In acute postoperative pain management intravenous lidocaine and/or ketamine have been advocated 
because of their morphine-sparing effect. 
The goal of this prospective, randomised, double-blind study was to assess morphine consumption with 
different regimens of intravenous infusion of lidocaine, ketamine or bath during 48 hours following 
laparotomy. Patients were randomised into four groups. Group L, K, and KL received intravenous 
lidocaine, ketamine or a combination, respectively, before incision and during 48 hours postoperatively. 
The contrai group (C) received a similar volume of saline bolus and infusion. Postoperative analgesia 
included morphine delivered by a patient-controlled analgesia device. Primary outcome was the 
cumulative morphine consumption and pain, sedation scores, pressure algometry and side effects were our 
secondary outcomes. Cognition and psychomotor performance were also tested. 
Out of 57 eligible patients, 44 completed the study. Lidocaine reduced the cumulative morphine 
consumption compared with the control group (mean 0.456 mg.kg-1 +/- 0.244 (SD) versus 0.705 +/-
0.442, respectively, P < 0.001). Pain scores during movement were statistically lower in all three 
treatment groups. Psychometric tests showed that the lidocaine group expressed more depressed feelings 
and sadness compared to the control group. 
Lidocaine administration had a morphine-sparing effect with a 36% reduction of morphine consumption 
while ketamine alone or combined with lidocaine did not. As a whole, our results suggest that intravenous 
lidocaine may offer advantages for postoperative analgesia. We propose lidocaine as a new alternative for 
pain control that needs to be studied further in future multicentric studies. 
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INTRODUCTION 
Optimal postoperative pain management facilitates rehabilitation immediately after abdominal surgery. 
Multiple studies have demonstrated that successful postoperative analgesia also reduces perioperative 
complications and improves patient comfort, thereby providing many benefits for the patient [1-3]. In 
addition, improved pain control during the perioperative period is one possible measure for the prevention 
of chronic postsurgical pain [ 4]. 
Opioids are frequently used for pain relief. Unfortunately, the vast interpatient variability to reach an 
optimal therapeutic level along with a host of adverse effects including nausea, vomiting, sedation, 
decreased intestinal motility and acute tolerance, limits its use in the postoperative period. 
Multimodal postoperative analgesia is a current trend in acute postoperative pain management. Different 
options are available including regional techniques such as epidural analgesia, peripheral nerve blocks, 
wound and intracavity infiltration. Other analgesic adjuncts are of increasing interest like N-methyl-D-
aspartate (NMDA) receptor antagonists (e.g., ketamine), anticonvulsants (e.g., gabapentine) and 
intravenous infusion oflocal anaesthetics [1-3]. 
Intravenous infusion of lidocaine (L) or ketamine (K) has recently been advocated for perioperative pain 
management [ 5-7]. Lidocaine acts mainly as a voltage-gated sodium channel blocker and shares analgesic, 
antihyperalgesic [8], antiallodynic effects as well as anti-inflammatory properties [9]. In recent studies, the 
use of intravenous lidocaine was shown to reduce morphine consumption, improve both pain control and 
bowel fonction after abdominal surgery [8, 10, 11]. 
Ketamine is an N-methyl-D-aspartate (NMDA) antagonist although it also has other mechanisms of 
action. NMDA receptors play an important role in synaptic plasticity and multiple experimental pain 
models have shown that blockade of the NMDA receptor reduces central sensitization induced by tissue 
injury [12,13]. Ketamine also reverses opioid-induced hyperalgesia and could thus reduce acute tolerance 
to opioids and delayed hyperalgesia [7,14]. Interestingly, several studies have demonstrated that ketamine 
at a low dose (in order to avoid psychomimetic si de effects) decreases both pain and morphine 
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consumption during the postoperative period [7, 15]. 
The aim of the present study was to evaluate the benefit of lidocaine and ketamine in the perioperative 
period of abdominal surgery. We conducted a placebo-controlled, randomised, double-blind prospective 
study and recorded morphine consumption that was our primary outcome. Pain scores at rest and during 
movement, sedation scores, pressure algometry, side effects and psychomimetic effects after systemic 
infusion of ketamine and lidocaine al one and combined were also measured. 
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METHODS 
The study was conducted between January 2006 and February 2007 at the Lausanne University Hospital 
Centre, a te1iiary-care teaching hospital in Switzerland. Adult patients (age 20 to 75 years) scheduled to 
undergo abdominal surgery by laparotomy were randomly assigned to a treatment or the control group. 
Exclusion criteria included laparoscopy, history of chronic pain, opioid self-administration, psychiatrie 
disorders, difficulties with communication, renal or hepatic dysfonction and an ASA physical status > III. 
The study was approved by our hospital's Institutional Ethics Committee. After patients had signed a 
written informed consent, they were randomised according to a double-blind design to one of four groups. 
Our hospital's central pharmacy was in charge of randomly assigning a treatment to each patient. A box 
containing the drug labelled with only the patient's name but no indication of the treatment was delivered 
to the investigators. In parallel, a rescue envelope with treatment specifics was sent to the postoperative 
care unit (PACU) and kept in a safe box. Table 1 summarises the four different regimens. Lidocaine (L) 
group received an IV bolus of lidocaine (1.5 mg.kg-1) at anaesthesia induction time (AI), followed by a 
continuous infusion of 2 mg.kg-1.h-1 intraoperative (IO) and 1.33 mg.kg-1.h-1 for 48 h postoperative (PO). 
Ketamine (K) group received a bolus of ketamine (0.5 mg.kg-1) at AI, then 0.25 mg.kg-1.h-1 IO followed 
by 0.1 mg.kg-1.h-1 for the first 24 h PO, then 0.05 mg.kg-1.h-1 for the next 24 h. Ketamine-lidocaine (KL) 
group received at AI a bolus injection of 1.5 mg.kg-' of lidocaine and 0.5 mg.kg-1 of ketamine, a 
continuous infusion of 1.3 mg.ki1 .h-1 of lidocaine and 0.17 mg.kg-1.h-1 of ketamine was delivered IO 
followed by 0.9 mg.kg-' of lidocaine with 0.08 mg.kg-1.h-1 of ketamine during 48 h PO, the dose of 
ketamine being reduced to 0.04 mg.kg-1.h-1 after the first 24 hours. The control group (C) received an 
equal volume of saline 0.9 % from AI to 48 h. The rate of infusion was similar for the four groups 
according to the patient's weight. 
Ex-vivo studies were performed by our central pharmacy before the stati of our study to establish the 
compatibility of the mixture of ketamine and lidocaine sin ce this is a non standard formulation. 
The day before surgery, patients were instructed on the use of the patient-controlled analgesia device 
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(PCA, Abbott Lifecare® 4200, Abbott AG, Baar/Zug, Switzerland) as well as the visual analogue scale 
(VAS) for pain. Psychometric tests, a modified Mini-Mental State Examination [16] and pressure 
algometry test [17] were explained and administered preoperatively. 
The day of the surgery, patients were premedicated one hour before surgery with oral midazolam 7.5 mg. 
Anaesthesia was induced with fentanyl 3 mcg.kg-1, propofol 2 mg.kg-1, vecuronium 0.1 mg.kg-1 and 
maintained by boluses of fentanyl and inhaled sevoflurane. Maintenance of anaesthesia was left to the 
discretion of the respective anaesthesiologist in charge. Ventilation and hemodynamic were adapted to 
obtain optimal conditions. Fentanyl consumption and awakening time were recorded. Immediately after 
orotracheal intubation and before surgical incision, a bolus of either L, K, KL or NaCl 0.9% according to 
the randomisation was administered and the infusion prepared by our pharmacy started. 
All patients received 1 g of intravenous (IV) paracetamol 30 minutes before the end of the surgical 
procedure. In the PACU, pain was controlled by titration of IV morphine. Boluses of 2 mg were 
administrated by the nurse until the V AS pain score was < 3/10 cm. Thereafter, postoperative analgesia 
consisted of IV morphine delivered by PCA (1 mg.mr1 morphine and 0.03 mg.mr1 droperidol), IV 
paracetamol (1 g/6 h) and the regimen of the study according to the assigned group. The parameters of the 
PCA were morphine 1 mg bolus with a minimum interval of 7 minutes and a maximum dose of 24 mg/4 
hours. PCA was started in the P ACU as soon as V AS was < 3 and compatible with an awakening state 
(sedation score < 2). Time to the first PCA request was defined as the time between the arrival in the 
PACU and the patient' s first self-administration of morphine. After 2 hours in the PACU, the patients 
were transferred to the surgi cal department where a regimen of morphine PCA was continued for a total of 
48 hours, together with IV paracetamol. 
The primary outcome of the study was the cumulative morphine consumption over 48 hours 
postoperatively. Morphine consumption was recorded at 30, 60, 120 minutes and at 4, 12, 24, 36, 48 hours 
using the PCA software. 
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Predefined secondary outcomes were pain scores (0-10 cm VAS) at rest and during coughing and/or 
movement, sedation scores (simplified Ramsay score with 4 levels; 0: awake, 1: sleepy, 2: easily roused, 
3: difficult to rouse ), mechanical hyperalgesia using pressure algometry (Somedic Sales AB, Hürby, 
Sweden, in kPa) and occurrence of sicle effects (sedation, nausea, vomiting, itching, nightmares ). Pressure 
algometry was recorded in the proximity of the incision. A five-point Lickert scale from 0 ("not at all") to 
4 ("extremely") was used to rate the following mood states: anxious, happy, relaxed, drowsy, tired, 
clumsy, alert, energetic, sad and depressed [18]. Cognition was assessed using a modified Mini-Mental 
State Examination (MMSE) [16,19] and psychomotor performance was tested using the Choice Reaction 
Time test [20]. The time of the first bowel movement after surgery was recorded for each patient. 
Statistical analysis 
We designed the study and sample size (11 patients per group) so as to detect a 30% (with a SD being ± 
20%) reduction in morphine requirement with a power of 80% and a type I error of 5%. All data are 
expressed as a mean ± SD. The Chi-square test was used to assess differences between groups for 
categorical variables. A two-way analysis of variance for repeated measures on one way (time) was used 
for assessing group and time effects as well as interactions for the total consumption of morphine during 
48 hours. A p < 0.05 with control group was considered statistically significant. A post hoc t-test with 
Bonferroni correction was used since we compared each experimental group (K; L; KL) with control 
group (C). The statistical analysis was performed using the JMP 7 statistical package (SAS Institute Inc, 
Cary, NC). 
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RESULTS 
Out of a total of 57 eligible patients, 52 were included and 44 (n = 11 in each group) completed the study. 
Exclusion criteria and patient withdrawal are explained in Figure 1. 
As to demographics, the four groups were comparable with regard to age, sex, weight, height and ASA 
status (Table 2). 
The duration of the surgi cal procedures ( expressed in minutes) was not different between the four groups 
(L: 157.5 ± 46.8, K: 177.0 ± 46.0, KL: 173.5 ± 82.0, C: 174.7 ± 84.9, p = 0.90). 
Surgical procedures were comparable across the four groups (p = 0.63, Table Sl). There was no 
perioperative mortality ( < 30 days) and the duration of hospitalisation ( days ± SD) was not statistically 
different between the four groups (K: 9.0 ± 3.3, L: 8.3 ± 5.3, KL: 8.2 ± 4.1, C: 8.3 ± 3.7, p = 0.96). None 
of the study patients had complications requiring admission to the intensive care unit. 
Intraoperative fentanyl consumption was significantly lower in the KL group than in the control group: 
143.4 ± 35.4 mcg.h-1 vs. 212.4 ± 43.8 mcg.h-1, respectively (p = 0.02). 
Total cumulative morphine consumption (mean expressed in mg.kg-1 ± SD) during the 48 h observation 
period was significantly lower in the lidocaine group compared with the control group (0.456 ± 0.244 
versus 0.705 ± 0.442, respectively, p < 0.0001, Figure 2). There was no statistically significant difference 
between K, KL and the control group (p = 0.48 and 0.43, respectively). 
From two hours to 48 hours postoperatively, VAS at rest was < 3/10 cm (Figure 3). No statistical 
difference was noted for the three groups compared to the control group during any of the observed 
periods (L: p = 0.17, K: p = 0.89, KL: p = 0.08). During movement "dynamic" V AS (Figure 4) was 
statistically different for all groups compared to the control group during the 48 hours of observation time 
(L: p = 0.004, K: p = 0.046, KL: p = 0.006). 
No significant differences were found in the mean time (minutes ± SD) to the first morphine 
administration by PCA among groups (L: 97.3 ± 63.5, K: 208.8 ± 356.7, KL: 78.2 ± 80.9, C: 105.5 ± 68.5, 
p = 0.37). 
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A trend towards higher threshold values for the algometry pressure test (Table 3) was noted in the groups 
L, K and KL versus the control group at 24 hours (p = 0.07). 
With regard to psychometric tests at 48 h, patients in the lidocaine group expressed more depressed 
feelings and sadness according to the five-point Lickert scale compared to the control group (1.0 ± 1.4 vs. 
0.2 ± 0.4, p = 0.01 and 1.1 ± 1.4 vs. 0.2 ± 0.4, respectively, p = 0.01). None of the other Lickert scale 
measures (anxiousness, happiness, relaxed sensation, drowsiness, tiredness, clumsiness, alertness and 
energetic state) showed a statistically significant difference across groups. The results of the modified 
Mini-Mental State Examination (MMSE) did not demonstrate any difference at the varions points 
measured (preoperatively, 4, 24 and 48 hours postoperatively). 
The results of the coordination Choice Reaction Time test were not different among the four groups for 
the coordination time variable (Figure SA), but number of errors was statistically lower in the K group 
versus the control group during the 48-hour observation period (p = 0.02, Figure SB). 
Time to awakening from anaesthesia did not differ among the four groups. Mean times were between S.2 
and 8.S minutes (p = 0.36). No delayed awakening was observed. Sedation was significantly increased in 
the ketamine group at lS and 30 minutes after arrivai to the PACU, but did not increase thereafter (Table 
4). The incidence of postoperative nausea, vomiting and nightmares was also similar among groups (p = 
O.S8 and 0.88, respectively, Table S2). 
Postoperative recovery of bowel function (mean in hours ± SD) was not significantly accelerated in any 
group (L: S7.0 ± 28.S, K: 40.0 ± 13.8, KL: 4S.3 ± 8.0, C: 44.0 ± 9.7, p = 0.39). 
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DISCUSSION 
The present study demonstrates that administration of preincisional and perioperative intravenous 
lidocaine during 48 hours associated with postoperative morphine PCA provides superior analgesia. This 
was confirmed by total cumulative morphine consumption over a 48-hour period that was lower in the 
lidocaine group when compared to patients receiving only morphine by PCA. 
Intravenous lidocaine showed a postoperative opioid-sparing effect (primary outcome) as well as 
improved pain scores with more improvement during movement than at rest. 
Pain is a complex and multifactorial phenomenon [21] and requires multimodal therapy [1-3] that has 
been proven to be more effective and with reduced analgesic-related side effects in the management of 
postoperative pain than with a single analgesic [1,3]. 
Non-opioid strategies of pain contrai during the perioperative period have recently emerged [21]. The goal 
to reduce morphine consumption has several benefits for the patient, including reduced opioid side effects, 
less nausea and a more rapid recovery of bowel fonction. In addition, recent data suggest that extensive 
use of opioids is associated with hyperalgesia and allodynia [22]. 
Sorne studies have evaluated the analgesic efficacy of ketamine [6, 15] and systemic local anaesthetics like 
lidocaine [5,23,24] but few have evaluated the combination of the two medications. Many trials describe a 
decrease in analgesia requirement after lidocaine infusion in the postoperative period [23] and other 
clinical studies with patients undergoing major abdominal surgery have also shown a morphine-sparing 
effect of intravenous lidocaine [25]. Reducing postoperative pain, especially during movement, is 
important in facilitating a timely acute rehabilitation program [26]. 
Local anaesthetics appear to reduce inflammation [27] and suppress C-fiber activity [28] making them 
potential analgesia drugs for postoperative pain. The anti-inflammatory properties of lidocaine are 
involved in blocking neutrophil accumulation at the injury site [5] and in reducing the release of 
inflammatory mediators [29] but the main therapeutic effect is attributed to a central antihyperalgesic 
effect [30]. 
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As to adverse effects of lidocaine, more sadness and depression were described by the patients in our 
study at 48 hours. However, we did not observe any coordination trouble of clinical relevance when using 
the coordination test during the 48 hours postoperatively. 
Ketamine is a phencyclidine derivative formulated as a racemic mixture that binds noncompetitively to the 
phencyclidine binding site of NMDA receptors and also modifies them by allosteric mechanisms [6]. This 
NMDA receptor antagonist has a significant opioid-sparing effect. The addition of a small intravenous 
dose of ketamine to local anaesthetics, opioids or other analgesic agents results in superior analgesia with 
significant morphine sparing and less sedation [31,32]. It has been shown to be particularly useful as an 
adjunct for patients receiving chronic opioids, patients in whom pain is poorly controlled in spi te of high-
dose opioid therapy. The adverse effects of ketamine, like psychomimetic effects, often limit the value of 
its use. The optimal dosing and the duration of administration [33] remain unclear but adverse effects are 
not significantly increased with small doses of ketamine. Low-dose ketamine has been defined as a bolus 
of< 1 mg.kg-' IV and an infusion rate<= 1.2 mg.kg-1.h-1 [34]. A review ofrandomised trials [15] showed 
that a wide range of ketamine regimens was used. In sixteen out of 53 trials, cumulative morphine 
consumption was significantly reduced with concomitant prophylactic intravenous ketamine (median 
dosage 0.4 mg.kg-1). That review concluded that the role of ketamine as a component of perioperative 
analgesia remains unclear [15]. 
In contrast to the lidocaine group, we did not observe a benefit of analgesia when administering ketamine 
or ketamine with lidocaine. On the other hand, we did not observe psychomimetic disorders in the K or 
KL group as we did in the L group. 
In our study, we were unable to confirm an improvement in postoperative bowel fonction [10] or a 
shortened hospital stay [26,35] as has been demonstrated in other studies. This can be explained by the 
low number of patients recruited, sufficient to notice a difference in our primary outcome morphine 
consumption (initial sample calculated) but inadequate to discriminate other effects ( other secondary 
outcomes recorded). Indeed, patient recruitment was laborious because of the increasing incidence of 
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laparoscopy in our institution that was an exclusion criterion and we suggest that additional studies must 
be conducted with another surgery type in order to investigate the potential of lidocaine on other 
outcomes. In addition, due to the wide range of lidocaine and ketamine infusion protocols (including 
dosing and duration of infusion) used in different studies, this too may have contributed to the difference 
in results. We are conscious of the fact that our study implies a low number of patients but we hope that 
our results can motivate conduct of others studies to confirm the interesting effect of lidocaine on pain 
control and optimise the best regimen for lidocaine infusion, including dosing and duration. 
In conclusion, our study confirmed a beneficial effect of lidocaine administration during the first 48 hours 
postoperatively in combination with morphine PCA to control pain after laparotomy. We therefore suggest 
that lidocaine may be an interesting alternative for pain control for the growing number of patients not 
suited for neuraxial anaesthesia who may benefit from the opioid-sparing effect of lidocaine. 
No external funding and no competing interests declared. 
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TABLES 
Table 1 Regimens of intravenous lidocaine, ketamine, association of ketamine and lidocaine, control 
group. 
Ketamine-
Lidocaine Ketamine Control 
lidocaine (n=ll) (n=ll) 
(n=ll) 
(n=ll) 
L* 1.5 
Equal bolus 
Bolus after induction; mg.kg-1 1.5 0.5 volume 
Kt0.5 
ofNaCl 0.9% 
L* 1.3 
Equal infusion 
Intraoperative infusion; mg.kg-1.h-1 2.0 0.25 volume 
Kt 0.17 
ofNaCl 0.9% 
1.33 0.1 L* 0.9 
Equal infusion 
Postoperative infusion 0-24h; mg.kg-1.h-1 volume 
Kt 0.08 
ofNaCl 0.9% 
L* 0.9 Equal infusion 
Postoperative infusion 24-48h; mg.kg-1.h-1 
1.33 0.05 
Kt 0.04 volume 
ofNaCl 0.9% 
*L: lidocaine; t K: ketamine 
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Table 2 Demographic data of patients receiving lidocaine, ketamine, ketamine and lidocaine or saline. 
Values are expressed as mean ± SD. 
Ketamine-
Lidocaine Ketamine Control 
lidocaine p value 
group (n=l1) group (n=l1) group (n=l1) 
group (n=l1) 
Male/Female 10/1 11/0 10/1 11/0 0.55 
Age (years) 60.8 ± 8.4 60.1±9.1 61.6 ± 5.8 58.6 ± 9.7 0.85 
Weight (kg) 77.3 ± 11.8 74.4 ±10.2 80.4 ± 12.0 81.0 ± 12.5 0.63 
Height (cm) 174 ± 5.6 172 ± 7.9 173 ± 7.3 174±9.1 0.87 
ASA VII/III 0/10/1 0/10/1 1/9/1 0/11/0 0.64 
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Table 3 Pressure algometry before and after laparotomy in the four groups. Values are expressed in kPa as 
mean± SD. 
Ketamine Ketamine-
Lidocaine Control 
group lidocaine p value 
group (n=11) group (n=11) 
(n=11) group (n=11) 
Before surgery 779.3 ± 341.0 675.8 ± 300.3 747.8 ± 304.6 717.0 ± 342.3 0.89 
lh 475.6 ± 196.5 401.3 ± 272.3 556.1 ± 361.7 297.0 ± 165.5 0.13 
2h 463.5 ± 177.8 431.8 ± 265.9 549.3 ± 424.9 337. 7 ± 188.6 0.37 
4h 390.6 ± 143.5 430.2 ± 259.8 550.2 ± 473.2 305.9 ± 155.3 0.27 
24h 281.4 ± 75.7 293.5 ± 119.1 375.8 ± 200.5 225.9 ± 81.1 0.07 
48h 323.8 ± 153.9 298.0 ± 150.6 427.4 ± 192.1 333.8 ± 184.1 0.35 
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Table 4 Sedation score after surgery in the four groups. Values are expressed as mean ± SD. The sedation 
score used is the simplified Ramsay score with 4 levels (0: awake, 1: sleepy, 2: easily roused, 3: difficult 
to rouse). 
Ketamine-
Lidocaine Ketamine Control 
lidocaine p value 
group (n=11) group (n=11) group (n=11) 
group (n=11) 
15' 0.9 ± 0.7 1.4 ± 1.0* 1.4 ± 1.0 0.4 ± 0.7 0.04* 
30' 0.6 ± 0.7 1.3 ± 0.9* 0.6± 0.7 0.3 ± 0.5 0.02* 
60' 0.5 ± 0.7 1.0 ± 0.8 0.4 ± 0.7 0.3 ± 0.5 0.14 
2h 0.5 ± 0.7 0.5 ± 0.7 0.3 ± 0.6 0.1±0.3 0.38 
4h 0.4 ± 0.5 0.4 ± 0.8 0.4 ± 0.7 0.2 ± 0.4 0.70 
24h 0.0 ± 0.0 0.1±0.3 0.3 ± 0.5 0.1±0.3 0.25 
48h 0.1±0.3 0.2 ± 0.4 0.1±0.3 0.1±0.3 0.38 
* p < 0.05 
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Figure 1 Flow diagram 
L: lidocaine group, K: ketamine group, KL: ketamine-lidocaine group, C: control group 
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Figure 2 Cumulative morphine consumption (mg.kg-1) over 48 hours in patients receiving lidocaine (111111) 
(0.456 ± 0.244, *p < 0.0001) or ketamine (11) (0.823 ± 0.597) or ketamine-lidocaine (11111) (0.665 ± 0.595) 
or saline (t:) (0.705 ± 0.442).Values (mg.kg"1) are expressed as mean ± SD. 
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Figure 3 Pain score (VAS: visual analogue score) at rest after laparotomy in patients receiving 
lidocaine ( + ), ketamine (Ill), ketamine-lidocaine ( Â.) or saline d;;) . Data are expressed as mean ± SD. 
No statistical differences among groups. 
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Figure 4 Pain score (VAS: visual analogue score) during movement after surgery in patients receiving 
lidocaine ( +) (p < 0.005), ketamine (11) (p < 0.05), ketamine-lidocaine ( Â) (p < 0.01) or saline (x). Data 
are expressed as mean ± SD. 
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Figure SA Coordination time test in patients receiving lidocaine ( +), ketamine (Il), ketamine-lidocaine 
(A) or saline (lxl). No statistically significant difference was observed compared with the control group. 
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Figure 5B Coordination test: number of errors in patients receiving lidocaine ( +) , ketamine (Ill), 
ketamine-lidocaine ( ..t..) or saline (x). The number of errors was statistically lower in the ketamine group 
versus the control group over the 48 hours observed (p = 0.02). 
21 
Supplemental data 
Table Sl Surgical procedures: distribution of surgical procedures among the different groups is equal, 
p= 0.63. 
Ketamine-
Lidocaine Ketamine Saline 
Lidocaine 
group group group Total 
group 
(n=ll) (n=ll) (n=ll) 
(n=ll) 
Prostatic surgery 8 7 8 9 32 
Colorectal surgery 2 2 1 0 5 
Gastrie surgery 0 0 2 
Renal surgery 0 0 2 
Pancreatic surgery 0 0 0 
Retroperitoneal surgery 0 0 0 1 1 
Bladder surgery 0 0 1 0 
Total 11 11 11 11 44 
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Table S2 Incidence of side effects: results are expressed as number of patients with side effects during 48 
hours (n = 11 in each group). 
L: lidocaine group, K: ketamine group, KL: ketamine-lidocaine group, C: control group 
Patients with nausea- Patients with nightmares Patients with pruritus 
vomiting 
L K KL c L K KL c L K KL c 
0-48 h 5 5 2 3 2 1 2 1 3 5 7 1 
p 0.58 0.88 0.17 
23 
1. Kehlet H, Holte K. Effect ofpostoperative analgesia on surgical outcome. BrJ Anaesth 2001; 87: 62-
72. 
2. Joshi GP. Multimodal analgesia techniques and postoperative rehabilitation. Anesthesio! Clin North 
America 2005; 23: 185-202. 
3. Kehlet H, Dahl JB. The value of "multimodal" or "balanced analgesia" in postoperative pain treatment. 
AnesthAnalg 1993; 77: 1048-56. 
4. Kehlet H, Jensen TS, Woolf CJ. Persistent postsurgical pain: risk factors and prevention. Lancet 2006; 
367: 1618-25. 
5. Koppert W, Ostermeier N, Sittl R, Weidner C, Schmelz M. Low-dose lidocaine reduces secondary 
hyperalgesia by a central mode of action. Pain 2000; 85: 217-24. 
6. Himmelseher S, Durieux ME. Ketamine for perioperative pain management. Anesthesiology 2005; 
102: 211-20. 
7. Zakine J, Samarcq D, Lorne E, et al. Postoperative ketamine administration decreases morphine 
consumption in major abdominal surgery: a prospective, randomized, double-blind, controlled study. 
Anesth Analg 2008; 106: 1856-61. 
8. Dirks J, Fabricius P, Petersen KL, Rowbotham MC, Dahl JB. The effect of systemic lidocaine on pain 
and secondary hyperalgesia associated with the heat/capsaicin sensitization model in healthy 
volunteers. Anesth Analg 2000; 91: 967-72. 
9. Hollmann MW, Durieux ME. Local anesthetics and the inflammatory response: a new therapeutic 
indication? Anesthesiology 2000; 93: 858-75. 
10. Harvey KP, Adair JD, Isho M, Robinson R. Can intravenous lidocaine decrease postsurgical ileus and 
shorten hospital stay in elective bowel surgery? A pilot study and literature review. Am J Surg 2009; 
198(2):231-6. 
11. Koppert W, Weigand M, Neumann F, et al. Perioperative intravenous lidocaine has preventive effects 
on postoperative pain and morphine consumption after major abdominal surgery. Anesth Analg 2004; 
98: 1050-5. 
12. Woolf CJ, Thompson SW. The induction and maintenance of central sensitization is dependent on N-
methyl-D-aspartic acid receptor activation; implications for the treatment of post-injury pain 
hypersensitivity states. Pain 1991; 44: 293-9. 
13. Woolf CJ, Chong MS. Preemptive analgesia--treating postoperative pain by preventing the 
establishment of central sensitization. Anesth Analg 1993; 77: 362-79. 
14. Helmy SA, Bali A. The effect of the preemptive use of the NMDA receptor antagonist 
dextromethorphan on postoperative analgesic requirements. Anesth Analg 2001; 92: 739-44. 
24 
15. Elia N, Tramer MR Ketamine and postoperative pain--a quantitative systematic review of randomised 
trials. Pain 2005; 113: 61-70. 
16. Folstein MF, Robins LN, Helzer JE The Mini-Mental State Examination. Arch Gen Psychiat1y 1983; 
40: 812. 
17. Dahl JB, Rosenberg J, Molke Jensen F, Kehlet H Pressure pain thresholds in volunteers and 
herniorrhaphy patients. Acta Anaesthesiol Scand 1990; 34: 673-6. 
18. Mc Nair DM LM, Droppleman LF. POMS manual profile of mood states. San Diego, CA: 
EdiTS/Educational and Industrial Testing Service, 1992: 1-40. 
19. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the 
cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-98. 
20. Scott W A, Whitwam JG, Wilkinson RT. Choice reaction time. A method of measuring postoperative 
psychomotor performance decrements. Anaesthesia 1983; 38: 1162-8. 
21. Carr DB, Goudas LC. Acute pain. Lancet 1999; 353: 2051-8. 
22. Joly V, Richebe P, Guignard B, et al. Remifentanil-induced postoperative hyperalgesia and its 
prevention with small-dose ketamine. Anesthesiology 2005; 103: 147-55. 
23. Marret E, Rolin M, Beaussier M, Bonnet F. Meta-analysis of intravenous lidocaine and postoperative 
recovery after abdominal surgery. Br J Surg 2008; 95: 1331-8. 
24. Cui W, Li Y, Li S, Wang R, Li J. Systemic administration of lidocaine reduces morphine requirements 
and postoperative pain of patients undergoing thoracic surgery after propofol-remifentanil-based 
anaesthesia. Eur J Anaesthesiol 201 O; 27: 41-6. 
25. Koppert W. Opioid-induced hyperalgesia. Pathophysiology and clinical relevance. Anaesthesist 2004; 
53: 455-66. 
26. Kaba A, Laurent SR, Detroz BJ, et al. Intravenous lidocaine infusion facilitates acute rehabilitation 
after laparoscopie colectomy. Anesthesiology 2007; 106: 11-8. 
27. Eriksson AS, Sinclair R, Cassuto J, Thomsen P. Influence of lidocaine on leukocyte fonction in the 
surgical wound. Anesthesiology 1992; 77: 74-8. 
28. Woolf CJ, Wiesenfeld-Hallin Z. The systemic administration of local anaesthetics produces a selective 
depression ofC-afferent fibre evoked activity in the spinal cord. Pain 1985; 23: 361-74. 
29. Martin F, Cherif K, Gentili ME, et al. Lack of impact of intravenous lidocaine on analgesia, functional 
recovery, and nociceptive pain threshold after total hip arthroplasty. Anesthesiology 2008; 109: 118-23. 
30. Wallace MS, Ridgeway BM, Leung A Y, Gerayli A, Yaksh TL. Concentration-effect relationship of 
intravenous lidocaine on the allodynia of complex regional pain syndrome types I and II. 
Anesthesiology 2000; 92: 75-83. 
25 
31. Argiriadou H, Himmelseher S, Papagiannopoulou P, et al. Improvement of pain treatment after major 
abdominal surgery by intravenous S+-ketamine. Anesth Analg 2004; 98: 1413-8. 
32. Bell RF, Dahl JB, Moore RA, Kalso E. Perioperative ketamine for acute postoperative pain. Cochrane 
Database Syst Rev 2006: CD004603. 
33. Bilgin H, Ozcan B, Bilgin T, et al. The influence of timing of systemic ketamine administration on 
postoperative morphine consumption. J Clin Anesth 2005; 17: 592-7. 
34. Schmid RL, Sandler AN, Katz J. Use and efficacy of low-dose ketamine in the management of acute 
postoperative pain: a review of current techniques and outcomes. Pain l 999; 82: 111-25. 
35. Herroeder S, Pecher S, Schonherr ME, et al. Systemic lidocaine shortens length of hospital stay after 
colorectal surgery: a double-blinded, randomized, placebo-controlled trial. Ann Surg 2007; 246: 192-
200. 
26 
